Papers
2
Total Citations
64
H-Index
2
About
Paul Doan is a surgical oncologist whose research sits at the intersection of precision surgery and cancer immunotherapy for prostate cancer. His work focuses on two major frontiers: improving the intraoperative detection of metastatic disease and understanding how local treatments can trigger systemic anti-tumour immunity. In his landmark 2022 study on robot-assisted PSMA-radioguided surgery, Doan demonstrated the safety and feasibility of using a ⁹⁹ᵐTc-based radiotracer to help surgeons identify lymph node metastases in real time during robot-assisted radical prostatectomy. That paper has already garnered 51 citations, reflecting its immediate impact on the field of image-guided surgery. More recently, his 2024 IRE-IMMUNO study provided the first prospective evidence that irreversible electroporation—a non-thermal ablative technique—can downregulate local immune suppression and induce systemic T-cell activation in patients with intermediate-risk prostate cancer. With 13 citations in under a year, this work is shaping how clinicians think about the immunological consequences of focal therapy. Doan’s research bridges the gap between technical surgical innovation and the emerging paradigm of in situ vaccination, offering patients new possibilities for combining local control with systemic immune benefit.
Research Focus
Key Achievements
Top Papers
- 1
- 2